BioPharm Insight Releases CRO Report on Clinical Trial Activity in 3rd Quarter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Jefferies Cuts Price Target on Parexel (PRXL) to $67 Following Weak 1Q
October 27, 2016 9:33 AM EDTJefferies maintained a Hold rating on PAREXEL International (NASDAQ: PRXL), and cut the price target to $67.00 (from $72.50), following the company's 1Q earnings report. EPS fell 10c below consensus and guidance midpoint. PRXL's revenue shortfall accounted for ~4c. Updated guidance reduces revenue by... More
